Entolimod candidate granted U.S. patent extension

Cleveland BioLabs, Inc. (CBL) was granted an extended patent protection for its entolimod candidate radiation countermeasure and oncological therapeutic on Monday.

The entolimod compound is currently being developed by the company to serve as a treatment for acute radiation syndrome (ARS) caused by high levels of radiation exposure. The candidate consists of a recombinant protein that aids in the immune response against exposure. Clinical studies have shown that the drug is safe to use. The company reports mild flu-like symptoms, elevation of liver enzymes and decreased blood pressure in human studies. At this time, there are no approved treatments for ARS.

The protein stimulates immune response through the interaction with toll-like receptor 5 (TLR5), which plays a key role in the immune response process.

The company stated that the candidate shows cytotoxic effects to tumor cells, and a Phase One clinical study is currently taking place in the Russian Federation in advanced cancer patients.

The company holds 14 patents in the U.S. for developmental candidates and technology associated with oncology and biological defense applications.

“With the market's increasing focus on immunotherapies for multiple indications, including oncology, CBLI has a strong and varied patent estate that underpins the company's value," CBL CEO Yakov Kogan said.

Organizations in this Story

Cleveland Biolabs

Want to get notified whenever we write about Cleveland Biolabs ?
Next time we write about Cleveland Biolabs, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.